CN106255685B - 用于预防或治疗疟疾的三氨基嘧啶化合物 - Google Patents

用于预防或治疗疟疾的三氨基嘧啶化合物 Download PDF

Info

Publication number
CN106255685B
CN106255685B CN201580022719.8A CN201580022719A CN106255685B CN 106255685 B CN106255685 B CN 106255685B CN 201580022719 A CN201580022719 A CN 201580022719A CN 106255685 B CN106255685 B CN 106255685B
Authority
CN
China
Prior art keywords
methyl
compound
cyclopropyl
pyrimidine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580022719.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106255685A (zh
Inventor
S·哈米德·皮尔·穆罕默德
V·帕蒂尔
K·穆鲁甘
E·维萨尔劳·贝拉乐
A·赖楚尔卡尔
S·兰德厄
J·朴图尔
N·罗伊·乔杜里
G·山布哈格
K·考史克
P·伊耶
V·齐尔斯卡·萨姆班达穆尔斯
S·首拉普尔
S·那拉亚南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MMV Medicines for Malaria Venture
Original Assignee
MMV Medicines for Malaria Venture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MMV Medicines for Malaria Venture filed Critical MMV Medicines for Malaria Venture
Publication of CN106255685A publication Critical patent/CN106255685A/zh
Application granted granted Critical
Publication of CN106255685B publication Critical patent/CN106255685B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580022719.8A 2014-04-28 2015-03-26 用于预防或治疗疟疾的三氨基嘧啶化合物 Active CN106255685B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2142CH2014 2014-04-28
IN2142/CHE/2014 2014-04-28
PCT/EP2015/056496 WO2015165660A1 (en) 2014-04-28 2015-03-26 Triaminopyrimidine compounds useful for preventing or treating malaria

Publications (2)

Publication Number Publication Date
CN106255685A CN106255685A (zh) 2016-12-21
CN106255685B true CN106255685B (zh) 2019-08-20

Family

ID=52779638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580022719.8A Active CN106255685B (zh) 2014-04-28 2015-03-26 用于预防或治疗疟疾的三氨基嘧啶化合物

Country Status (22)

Country Link
US (1) US9957253B2 (https=)
EP (1) EP3137455B1 (https=)
JP (1) JP6529983B2 (https=)
CN (1) CN106255685B (https=)
AP (1) AP2016009570A0 (https=)
BR (1) BR112016024467B1 (https=)
CA (1) CA2946654C (https=)
CY (1) CY1120700T1 (https=)
DK (1) DK3137455T3 (https=)
ES (1) ES2696350T3 (https=)
HR (1) HRP20181816T1 (https=)
HU (1) HUE042043T2 (https=)
LT (1) LT3137455T (https=)
MX (1) MX374458B (https=)
MY (1) MY178971A (https=)
PH (1) PH12016502322B1 (https=)
PL (1) PL3137455T3 (https=)
PT (1) PT3137455T (https=)
RS (1) RS58124B1 (https=)
SI (1) SI3137455T1 (https=)
SM (1) SMT201800588T1 (https=)
WO (1) WO2015165660A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105699584B (zh) * 2016-02-03 2018-02-09 昆药集团股份有限公司 一种蒿甲醚相关物质的检测方法
WO2018079629A1 (ja) 2016-10-26 2018-05-03 カルナバイオサイエンス株式会社 抗マラリア活性を有する新規ピリミジン誘導体
CN106727584A (zh) * 2017-02-08 2017-05-31 于贵庆 一种治疗骨病的药物组合物
JP2020532513A (ja) * 2017-09-05 2020-11-12 カディラ ヘルスケア リミティド トリアミノピリミジン化合物およびその中間体の調製方法
CN117327007B (zh) * 2023-09-26 2024-09-13 上海陶术生物科技有限公司 一种vt107的制备方法
WO2025115034A1 (en) * 2023-11-30 2025-06-05 Zydus Lifesciences Limited A process for the preparation of a triaminopyrimidine compound and novel intermediates thereof
EP4574143A1 (en) 2023-12-21 2025-06-25 Universität Regensburg Inhibitors of plasmodia remodeling enzymes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CN101031558A (zh) * 2004-09-30 2007-09-05 泰博特克药品有限公司 抑制人类免疫缺陷病毒的5－杂环基嘧啶
WO2014058685A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CN101031558A (zh) * 2004-09-30 2007-09-05 泰博特克药品有限公司 抑制人类免疫缺陷病毒的5－杂环基嘧啶
WO2014058685A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential;Xianming Deng;《Bioorganic & Medicinal Chemistry Letters》;20100602;第20卷(第14期);第4030页表4、5、化合物40 *

Also Published As

Publication number Publication date
AP2016009570A0 (en) 2016-11-30
CA2946654A1 (en) 2015-11-05
MY178971A (en) 2020-10-26
EP3137455A1 (en) 2017-03-08
CN106255685A (zh) 2016-12-21
US20170050951A1 (en) 2017-02-23
RS58124B1 (sr) 2019-02-28
MX374458B (es) 2025-03-06
JP2017514804A (ja) 2017-06-08
PH12016502322B1 (en) 2022-03-23
PL3137455T3 (pl) 2019-01-31
MX2016014166A (es) 2017-02-14
PH12016502322A1 (en) 2017-01-30
BR112016024467B1 (pt) 2022-11-29
LT3137455T (lt) 2018-10-25
CA2946654C (en) 2022-08-23
EP3137455B1 (en) 2018-08-15
BR112016024467A2 (pt) 2017-08-15
WO2015165660A1 (en) 2015-11-05
HK1231478A1 (en) 2017-12-22
CY1120700T1 (el) 2019-12-11
SI3137455T1 (sl) 2019-01-31
US9957253B2 (en) 2018-05-01
HRP20181816T1 (hr) 2018-12-28
PT3137455T (pt) 2018-11-21
DK3137455T3 (en) 2018-12-10
SMT201800588T1 (it) 2019-01-11
JP6529983B2 (ja) 2019-06-12
ES2696350T3 (es) 2019-01-15
HUE042043T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
CN106255685B (zh) 用于预防或治疗疟疾的三氨基嘧啶化合物
TWI902715B (zh) 作為ｐａｒｐ７抑制劑的嗒酮
CN110248948B (zh) 墨蝶呤及其盐的多晶型物
US9050345B2 (en) Pyrrolotriazines as potassium ion channel inhibitors
JP7148532B2 (ja) セピプテリンの多形
EP3173412A1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
KR20170137200A (ko) Syk 억제제를 사용한 만성 이식편 대 숙주 질환의 치료
CN108349910A (zh) 葡萄糖摄取抑制剂
CN113677680B (zh) Egfr抑制剂及其组合物和应用
AU2020296063A1 (en) Targeted protein degradation of PARP14 for use in therapy
CN106029666B (zh) 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物
AU2016269626B2 (en) Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents
WO2019018359A1 (en) THIENO [2,3-D] PYRIMIDINES AND BENZOFURO (3,2-D) PYRIMIDINES USEFUL AS ANTIMICROBIAL AGENTS
CN116710425A (zh) 用于治疗涉及兰诺定受体的病症的药剂
US7507730B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators
US9403834B2 (en) Pyrrolotriazines as potassium ion channel inhibitors
US10155767B2 (en) Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
OA18110A (en) Triaminopyrimidine compounds useful for preventing or treating malaria
HK1231478B (en) Triaminopyrimidine compounds useful for preventing or treating malaria
CN117545747A (zh) 具有抗疟疾活性的杂环化合物的盐及其晶体
CN113527331A (zh) 硝基咪唑类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant